Filter and concentrator device for treatment of blood

• US 20040182783A1
• Filed: 03/17/2003
• Published: 09/23/2004
• Est. Priority Date: 03/17/2003
• Status: Abandoned Application

• Current Assignee: Hemavation LLC
• Original Assignee: Hemavation LLC
• Inventors: Walker, Kimberly A., Davidner, Alan A., Mallett, Scott R.
• Application Number:
  US10/391,445
• Publication Number:
  US 20040182783A1
• Time in Patent Office: Days
• US Class Current: 210/639
• CPC Class Codes: A61L 2/0011 using physical methods
• CPC Class Codes: A61L 2/0017 Filtration
• CPC Class Codes: A61M 1/3431 upstream of the filter
• CPC Class Codes: A61M 1/3468 using treated filtrate as substitution fluid
• CPC Class Codes: A61M 1/3472 with treatment of the filtrate
• CPC Class Codes: A61M 1/3482 by filtrating the filtrate using another cross-flow filter, e.g. a membrane filter
• CPC Class Codes: A61M 1/3486 Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
• CPC Class Codes: A61M 1/3623 Means for actively controlling temperature of blood
• CPC Class Codes: A61M 1/3681 by irradiation
• CPC Class Codes: A61M 2205/053 ultraviolet
• CPC Class Codes: A61M 2205/75 with filters

Abstract

A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodbome microorganisms, a hemoconcentrator/filtration unit to remove approximately 50-75% of target molecules from the patient blood and a filter unit to remove target molecules from patient blood from the sieved plasma filtrate. Target molecules are produced by microorganisms, as well as by the patient'"'"'s cells. These molecules include endotoxins from Gram negative bacteria, exotoxins from Gram negative and Gram positive bacteria, as well as RAP protein mediator from Staphylococcus aureus, and cell mediators such as tumor necrosis factor-alpha, and interleukin 1-beta, interleukin 6, complement proteins C3a and C5a, and bradykinin.

Claims

1. A method of treating a patient by removing one or more toxins from the patient'"'"'s blood, comprising:

removing at least a portion of the patient'"'"'s blood;

diluting said at least a portion of the blood with a diluent to provide diluted blood, thereby reducing the hematocrit of said at least a portion of the blood;

transporting the diluted blood to a concentrator with a flow rate of less than 400 ml/min;

concentrating the diluted blood using the concentrator thereby removing at least a portion of the diluent therefrom;

filtering said diluted blood to remove one or more toxins from said diluted blood, thereby producing treated blood; and

returning the treated blood to the patient.

2. The method of claim 1, wherein said concentrating step and said filtering step occur substantially simultaneously.

3. The method of claim 1, further comprising returning the diluent removed from the blood to a diluent source via a recycle path.

4. The method of claim 3, further comprising returning the diluent removed from the blood to a diluent source using a recycle path filter.

5. The method of claim 4, further comprising returning the diluent removed from the blood to a diluent source using an electrostatically charged, melt-blown material.

6. The method of claim 1, further comprising oxygenating the blood received from the patient.

7. The method of claim 1, further comprising heating at least a portion of the blood to about body temperature.

8. The method of claim 1, further comprising cooling at least a portion of the blood to about body temperature.

9. The method of claim 1, further comprising heating at least a portion of the blood to between about 34°

C. to about 42°

C.

10. The method of claim 1, further comprising heating at least a portion of the blood to between about 34°

C. to about 42°

C.

11. The method of claim 1, further comprising changing the temperature of at least a portion of the blood by about 1°

C. to about 10°

C.

12. The method of claim 1, wherein the step of transporting the diluted blood comprises transporting the diluted blood at a flow rate in the range of about 75 ml/min to about 125 ml/min.

13. The method of claim 1, wherein the step of transporting the diluted blood comprises transporting the diluted blood at a flow rate in the range of about 126 ml/min to about 200 ml/min.

14. The method of claim 1, wherein the step of transporting the diluted blood comprises transporting the diluted blood at a flow rate in the range of about 201 ml/min to about 300 ml/min.

15. The method of claim 1, wherein the step of transporting the diluted blood comprises transporting the diluted blood at a flow rate in the range of about 301 ml/min to 400 ml/min.

16. The method of claim 1, wherein the step of removing at least a portion of the patient'"'"'s blood comprises removing at least a portion of the patient'"'"'s blood having a hematocrit of greater than 36%.

17. The method of claim 1, further comprising providing at least one pump for moving said blood or diluent.

18. The method of claim 1, further comprising transporting blood and diluent through a pump with a flow rate of less than 400 ml/min.

19. The method of claim 1, wherein the step of concentrating the diluted blood comprises providing two hemoconcentrators connected in series.

20. The method of claim 1, wherein the step of concentrating the diluted blood comprises:

providing a hollow cylinder; and

providing a central core formed of hollow fibers axially disposed within said hollow cylinder.

21. The method of claim 20, wherein the step of providing a hollow cylinder comprises providing a hollow cylinder having a length of about 10 inches and a diameter of about 1.5 inches.

22. The method of claim 20, wherein the step of providing a central core comprises providing a central core having a surface area in the range of between about 1.2 m² to about 2.4 m².

23. The method of claim 1, wherein returning the treated blood to the patient further comprises providing tubing for the return path.

24. The method of claim 1, further comprising providing a reservoir connected to receive material filtered from the blood.

25. The method of claim 1, further comprising providing an inlet monitoring means for monitoring the pressure of the blood.

26. The method of claim 1, wherein the step of diluting the blood to provide diluted blood, thereby reducing the hematocrit of said blood further comprises reducing the hematocrit to about 5% to about 20%.

27. The method of claim 1, wherein the step of concentrating the diluted blood comprises providing a concentrator having a transmembrane pressure greater than 76 mmHg.

28. The method of claim 1, wherein the step of removing at least a portion of the patient'"'"'s blood comprises removing at least a portion of the blood from a patient having an inflammatory disease.

29. The method of claim 28, wherein the step of removing at least a portion of the patient'"'"'s blood comprises removing at least a portion of the blood from a patient having an inflammatory disease, wherein said inflammatory disease is selected from the group consisting of:

sepsis, acute renal failure, ischemic stroke, Sudeck'"'"'s syndrome, chronic fatigue syndrome, heat stroke, Hodgkin'"'"'s Disease, lupus, myocardial infarction, AIDS, viremia, HCV, HBV, tuberculosis, muscular dystrophy or multiple sclerosis, Acute Respiratory Distress Syndrome, and heart disease.

30. The method of claim 1, further comprising administering one or more vitamins to the blood.

31. The method of claim 1, further comprising exposing a portion of the patient'"'"'s blood to one or more vitamins in a dose sufficient to reduce at least one free radical in said portion of the patient'"'"'s blood.

32. The method of claim 30, further comprising administering one or more vitamins selected from the group consisting of one or more of the following:

Zn, Cu, manganese, selenium, vitamin A, C, E, B complex, K, P, lycopene, superoxide dismutase, co-enzyme Q10, catechins, polyphenols, flavanols, depsides, quinic acids, carotenoids, thearubigens, theaflavin, theaflavic acids and ethyl pyruvate.

33. The method of claim 32, wherein said depside is chlorogenic acid, coumaroylquinic acid or theogallin.

34. The method of claim 1, further comprising administering a cocktail consisting of vitamin A, vitamin C, vitamin E and zinc to a portion of the patient'"'"'s blood.

35. The method of claim 1, further comprising administering insulin therapy to a patient'"'"'s blood, comprising exposing a portion of the patient'"'"'s blood to insulin in a dose sufficient to facilitate cellular glucose entry.

36. The method of claim 1, further comprising administering nitroglycerin to a patient'"'"'s blood, comprising exposing a portion of the patient'"'"'s nitroglycerin in a dose sufficient to facilitate microcirculation.

37. A method for removing toxins from the blood of a patient comprising:

removing blood from the patient;

diluting the blood, thereby reducing the hematocrit of said blood and producing diluted blood;

transporting the diluted blood to a first filter with a flow rate of less than 400 ml/min;

filtering the diluted blood with the first filter to receive the blood and extract cell mediators and diluent therefrom to produce filtered blood;

re-filtering the filtered blood with a second filter to produce treated blood; and

returning the treated blood to the patient.

38. The method of claim 37, further comprising returning the diluent to a diluent source after re-filtering.

39. The method of claim 37, wherein the step of filtering the diluted blood comprises filtering the diluted blood using a filter with a porosity of about 70 kilodaltons to about 90 kilodaltons.

40. The method of claim 37, wherein the step of filtering the diluted blood comprises filtering the diluted blood using a filter material comprising polysulfone fibers.

41. The method of claim 37, wherein the step of re-filtering the filtered blood comprises filtering the filtered blood using a filter with a porosity of about 10 kilodaltons to about 30 kilodaltons.

42. The method of claim 37, wherein the step of re-filtering the filtered blood comprises filtering the filtered blood using two filters connected in parallel, each filter having a porosity of about 10 kilodaltons.

43. A blood treatment system comprising:

a diluent source for supplying a diluent to reduce the hematocrit of the blood;

a concentrator device to filter the diluted blood and to remove the diluent therefrom, said blood being received at a combined flow rate of less than 400 ml/min;

a pump to regulate flow rate of a fluid; and

a return path connected for returning filtered blood from said concentrator device to a blood source.